Syn-Ake
A synthetic tripeptide that mimics Temple Pit Viper venom, blocking muscular acetylcholine receptors to reduce dynamic wrinkles. Often called 'topical Botox' — reduces muscle contractions by 82% in vitro.
What is Syn-Ake?
Syn-Ake is a patented synthetic tripeptide designed to mimic the paralytic action of Waglerin-1, a peptide found in the venom of the Temple Pit Viper (Tropidolaemus wagleri). It acts as a reversible antagonist of the muscular nicotinic acetylcholine receptor (nmAChR), blocking the signal that tells facial muscles to contract. The result is a topical "Botox-like" muscle-relaxing effect that reduces dynamic wrinkles — the lines caused by repetitive facial expressions like frowning and squinting. At 0.5 mM concentration, Syn-Ake reduces muscle contractions by 82% in isolated tissue preparations. Unlike Botox, which completely paralyzes muscles via injection, Syn-Ake works topically with a gentler, partial relaxation that softens wrinkles without freezing facial expression.
What Syn-Ake Is Investigated For
Syn-Ake is investigated as a topical cosmetic anti-wrinkle active that mimics the postsynaptic neuromuscular-junction pharmacology of waglerin-1 from Temple Pit Viper venom, with ancillary claims around MMP inhibition and antioxidant activity. The strongest available evidence is the in vitro mechanism — 82% muscle contraction reduction at 0.5 mM in isolated tissue preparations and well-documented nmAChR antagonism — rather than in vivo clinical outcomes. Clinical efficacy data is limited to manufacturer-sponsored DSM/Pentapharm studies and multi-peptide formulation trials (the 2026 serum study with Argireline showed 10–13% dynamic wrinkle improvement over 12 weeks). The honest caveats are substantial. Independent human trials on Syn-Ake specifically are essentially absent, waglerin-1 itself shows roughly 100-fold species selectivity favoring mouse over human nmAChR, and whether the peptide actually reaches neuromuscular junctions in facial musculature at meaningful concentrations from topical application is the central unresolved question. The 'topical Botox' marketing framing overstates the effect size — botulinum toxin injection produces 50–80% dynamic wrinkle reduction within days, not comparable to topical Syn-Ake's softer, slower effect.
History & Discovery
Syn-Ake was developed by Pentapharm (now part of dsm-firmenich) in Switzerland in the early 2000s and trademarked as a synthetic biomimetic of waglerin-1, a 22-amino-acid peptide isolated from the venom of the Temple Pit Viper (Tropidolaemus wagleri). Waglerin-1 acts as a competitive antagonist at the muscular nicotinic acetylcholine receptor (nmAChR), blocking acetylcholine binding at the postsynaptic neuromuscular junction — the venom mechanism that causes flaccid paralysis in prey species. Pentapharm's design distilled this venom pharmacology down to a much smaller synthetic dipeptide derivative (dipeptide diaminobutyroyl benzylamide diacetate) intended to retain receptor binding while being practical to synthesize and formulate. The launch positioning was unmistakable: 'topical Botox' that worked at the muscle receptor instead of the nerve terminal, with the snake-venom story as a marketing centerpiece. Independent academic literature on the synthetic peptide is thin — most efficacy claims trace back to manufacturer-associated studies — and the regulatory and clinical framing has remained firmly within the cosmeceutical category rather than progressing toward drug-style evidence development.
How It Works
When you frown or squint, nerves release acetylcholine to tell facial muscles to contract. Over time, these repeated contractions create wrinkles. Syn-Ake blocks the receptor on the muscle side — like putting a lock on the door so the contraction signal can't get through. The muscles partially relax, and the wrinkles they create soften and smooth out.
Syn-Ake (dipeptide diaminobutyroyl benzylamide diacetate) is a synthetic analog of Waglerin-1, a 22-amino acid peptide from Tropidolaemus wagleri venom. It acts as a reversible competitive antagonist at the epsilon (ε) subunit of the muscular nicotinic acetylcholine receptor (nmAChR), blocking acetylcholine binding and inhibiting muscle depolarization. At 0.5 mM, it reduces muscle contraction by 82% in isolated tissue preparations within 2 hours. This postsynaptic mechanism is complementary to presynaptic approaches like Argireline (SNARE complex inhibition) and SNAP-8. In silico studies demonstrate binding to MMP-13 (strongest), MMP-8, and MMP-1, suggesting additional anti-aging activity through matrix metalloproteinase inhibition that would protect collagen and elastin from enzymatic degradation. SIRT1 binding at -9.32 kcal/mol and dose-dependent DPPH radical scavenging indicate ancillary antioxidant and sirtuin-modulating properties. A 2026 clinical study of a serum containing Syn-Ake plus Argireline showed 35-69% static wrinkle improvement and 10-13% dynamic wrinkle improvement over 12 weeks.
Evidence Snapshot
Human Clinical Evidence
Limited. A controlled clinical study with 4% Syn-Ake over 28 days showed statistically significant wrinkle reduction (manufacturer data, DSM/Pentapharm). A 2026 clinical study (50 participants, 12 weeks) of a multi-peptide serum containing Syn-Ake and Argireline showed 35-69% static wrinkle improvement, 10-13% dynamic wrinkle improvement, and significant gains in smoothness, elasticity, and firmness (PMID: 41668671). However, multi-ingredient formulations make attribution to Syn-Ake specifically difficult.
Animal / Preclinical
Limited. Primarily in vitro: 82% muscle contraction reduction at 0.5 mM in isolated tissue preparations. Molecular docking and dynamics simulations confirmed stable binding to nmAChR, MMP-13, MMP-1, and SIRT1 (PMID: 37349941). Cytotoxicity and genotoxicity testing confirmed safety parameters.
Mechanistic Rationale
Moderate. The nmAChR antagonism mechanism is pharmacologically sound and well-characterized for Waglerin-1 venom peptides. The synthetic tripeptide's ability to replicate this activity topically through intact skin at cosmeceutical concentrations is the key question — in vitro receptor binding is demonstrated, but in vivo transdermal delivery efficiency is uncertain.
Research Gaps & Open Questions
What the current literature has not yet settled about Syn-Ake:
- 01Independent, non-industry-funded human trials on Syn-Ake specifically — the existing efficacy claims are dominated by Pentapharm/DSM-associated studies, and rigorous peer-reviewed independent replication of effect sizes is largely absent.
- 02Direct head-to-head comparisons with botulinum toxin (the implicit comparator in the marketing) and with other cosmetic neuromodulator peptides (Argireline, Vialox, Pentapeptide-18) at matched concentrations and durations.
- 03Real-world skin-penetration and target-site quantification across commercial formulations — whether the peptide actually reaches nmAChRs in facial musculature in clinically meaningful concentrations from topical application is the central unresolved question.
- 04Long-term human data — most published work spans 28-day to 12-week windows; multi-month and multi-year continuous use has not been studied as a distinct safety or efficacy question.
- 05Whether stacking Syn-Ake with similar postsynaptic peptides (Vialox) produces additive benefit or redundant target-site occupancy.
- 06Translation of in vitro effect sizes (82% contraction reduction at 0.5 mM in isolated tissue) to in vivo human outcomes — the gap between mechanism strength and clinical effect size is large and informative.
Forms & Administration
Syn-Ake is used topically in cosmeceutical formulations — serums, creams, and eye treatments. Standard concentrations are 1-4% in finished products. Often combined with Argireline (presynaptic) and/or Matrixyl (collagen stimulation) for multi-target anti-aging. Applied to clean skin, typically twice daily. No prescription required for cosmeceutical products.
Dosing & Protocols
The ranges below reflect protocols commonly discussed in the literature and by clinicians — not a prescription. Actual dosing for any individual should be determined by a qualified healthcare provider who knows the patient.
Typical Range
Cosmetic formulations typically include Syn-Ake at 1–4% of the finished product, with manufacturer efficacy testing centered on around 4% concentration. Over-the-counter Syn-Ake serums commonly fall in the 1–3% range; some specialty products advertise higher concentrations, but stratum corneum permeation is the practical rate-limiting step and the upper end of the range yields diminishing returns.
Frequency
Applied topically once or twice daily to clean skin, targeting expression-line areas (forehead, glabella, crow's feet, perioral lines). Manufacturer studies typically used twice-daily application for 28 days before measuring wrinkle-depth endpoints; multi-peptide trials extend to 12 weeks.
Timing Considerations
No specific timing requirements: can be administered at any time of day, with or without food, and is not tied to exercise timing. Consistency matters more than the specific clock — dose at roughly the same time each day (or same day each week, for weekly protocols) to keep exposure steady.
Cycle Length
Continuous indefinite use. Syn-Ake is a maintenance cosmetic active — the competitive, reversible nmAChR antagonism only operates while peptide is present at the receptor, so measurable benefit requires continued application. No cycling strategy is described in the cosmetic literature.
Protocol Notes
Skin penetration is the central practical caveat. The synthetic dipeptide derivative is smaller than the parent waglerin-1 venom peptide, which is a deliberate design choice for transdermal delivery, but it is still hydrophilic and faces the same stratum corneum barrier as other cosmetic peptides. The pharmacological target — nmAChRs at neuromuscular junctions in facial musculature — sits well below the epidermal layers that topical peptides typically reach, which is the fundamental gap between in vitro receptor binding (82% contraction reduction at 0.5 mM in isolated tissue preparations) and modest in vivo wrinkle-depth effects. Syn-Ake is commonly stacked with Argireline (presynaptic SNARE-complex inhibition) on the rationale that hitting the neuromuscular junction from both pre- and postsynaptic sides should produce additive effects. It is also frequently combined with matrikine peptides (Matrixyl, Syn-Coll) for collagen support and with Vialox or Pentapeptide-18 in 'multi-target neuromodulator' product positioning. Head-to-head clinical evidence supporting stacking superiority over single-peptide products is limited. Waglerin-1 itself shows roughly 100-fold species selectivity favoring mouse over human nmAChR — an important note when interpreting how directly mouse or in vitro receptor data translates to human facial musculature.
Syn-Ake is a cosmetic ingredient, not a drug. It is not FDA-approved to treat or prevent any medical condition, and cosmetic claims permitted on labels are limited to appearance-related language. Do not inject cosmetic peptide products — there is no authorized injectable category for Syn-Ake and documented infection risk exists for unlicensed injection of cosmetic peptides.
Timeline of Effects
Onset
Manufacturer-sponsored studies typically begin to report measurable wrinkle-depth reduction at 14–28 days of twice-daily application. Immediate 'tightening' or smoothing sensations within minutes of application come from film-forming polymers and humectants in the vehicle, not from real-time receptor blockade.
Peak Effect
Maximum measured effect in manufacturer studies is typically reported around 28 days at 4% concentration. Multi-peptide trials combining Syn-Ake with Argireline report 35–69% improvement in static wrinkle measures and a more modest 10–13% improvement in dynamic wrinkle measures over 12 weeks — though attribution to Syn-Ake specifically is difficult in multi-ingredient formulations. For comparison, botulinum toxin injection reduces dynamic wrinkle severity by 50–80% within days; topical Syn-Ake effects, where present, are softer in magnitude and develop over weeks.
After Discontinuation
Effects recede over weeks as the peptide is cleared and nmAChR function returns to baseline. Most users describe a gradual return toward baseline expression-line depth within 4–8 weeks of stopping use. There is no described withdrawal or rebound pattern.
Common Questions
Who Syn-Ake Is NOT For
- •Broken, irritated, or actively inflamed skin — wait until the skin barrier is intact before applying cosmetic peptide serums; application to compromised skin increases irritation potential and any systemic absorption.
- •Known hypersensitivity to Syn-Ake or to other components of the cosmetic vehicle (preservatives, fragrances, emulsifiers); contact dermatitis is uncommon but reported.
- •Pregnancy and breastfeeding — topical cosmetic use on intact skin is generally considered low-risk, but there is no dedicated safety data in pregnancy, and the receptor-targeting mechanism makes a conservative default to minimize use during this window reasonable.
- •Pediatric use — no data and no clinical reason for children or adolescents to use anti-wrinkle peptides.
- •Do not inject cosmetic Syn-Ake preparations — these are not sterile injectable products, not manufactured under injectable standards, and there is no clinical basis for injection.
- •Patients with pre-existing neuromuscular disorders (myasthenia gravis, Lambert-Eaton syndrome) should consult a clinician before using nmAChR-targeting cosmetic peptides, even though systemic exposure from topical use is expected to be negligible.
Drug & Supplement Interactions
Documented pharmacological drug interactions for topical Syn-Ake are minimal. Systemic absorption from typical topical use is low enough that meaningful interaction with oral or injected medications is not expected. The practical interaction space is topical layering with other actives. Syn-Ake is compatible with most cosmetic ingredients — niacinamide, hyaluronic acid, ceramides, and other peptides layer readily. Co-formulation with Argireline is common and marketed as synergistic on the rationale that pre- and postsynaptic mechanisms hit different points in the same neuromuscular cascade. Stacking with Vialox (which targets a similar postsynaptic receptor) is common but raises a redundancy question — if both peptides compete for the same nmAChR site, additive benefit is theoretically capped. Layering with matrikine peptides (Matrixyl, Syn-Coll) combines independent mechanisms. High-concentration L-ascorbic acid (vitamin C) is acidic enough that concurrent same-layer application can destabilize peptide actives and is typically used at a different time of day. Strong AHA/BHA exfoliation on the same evening as Syn-Ake can reduce peptide activity at the surface and increase irritation, so spacing is sensible. There is no documented concern with oral medications, systemic hormones, or anticoagulants at the level of topical cosmetic exposure. Patients receiving botulinum toxin injection generally do not need to stop Syn-Ake beforehand, though some clinicians prefer a washout to simplify assessment.
Safety Profile
Common Side Effects
Cautions
- • Not FDA-approved as a drug — marketed as a cosmeceutical ingredient
- • Topical efficacy is limited by skin penetration — not as potent as injectable muscle relaxants
- • Clinical studies often use multi-ingredient formulations, making it hard to isolate Syn-Ake's specific contribution
- • Over-the-counter products vary widely in concentration and formulation quality
What We Don't Know
Long-term effects of chronic topical nmAChR antagonism on facial muscles are not studied. Whether meaningful receptor blockade occurs through intact skin at cosmeceutical concentrations is debated. Most clinical data comes from manufacturer-sponsored studies (DSM/Pentapharm). Independent clinical replication is limited.
Legal Status
United States
Regulated as a cosmetic ingredient under FDA cosmetic law, not as a drug. Over-the-counter sale in finished cosmetic formulations is permitted without prescription. Syn-Ake (dipeptide diaminobutyroyl benzylamide diacetate) is INCI-listed and appears in many over-the-counter anti-wrinkle products. Not approved as a drug for wrinkles or any other medical indication — labels are limited to cosmetic appearance claims. The 'snake venom' marketing language describes biomimetic design inspiration, not source material; the ingredient is fully synthetic.
International
Permitted as a cosmetic ingredient across the EU (CosIng database), UK, Canada, Australia, Japan, and most major markets. Cosmetic ingredient safety reviews have not raised concerns at typical formulation levels. Some Asian markets (notably Korea and Japan) have particularly active 'snake venom peptide' product categories built around Syn-Ake.
Sports & Competition
Not listed on the WADA Prohibited List and not a realistic doping concern. Topical cosmetic peptides have negligible systemic exposure relevant to performance.
Regulatory status changes over time. Verify current local rules with a qualified professional.
Myths & Misconceptions
Myth
Syn-Ake is 'topical Botox' and produces comparable results to injection.
Reality
The marketing framing is misleading. Syn-Ake competitively and reversibly blocks the muscle nicotinic acetylcholine receptor; botulinum toxin enzymatically cleaves SNARE proteins inside nerve terminals to abolish acetylcholine release entirely. Botulinum toxin produces 50–80% wrinkle reduction within days; topical Syn-Ake, when effective, produces softer reductions over weeks. The mechanisms are different, the magnitudes are different, and Syn-Ake does not substitute for injection.
Myth
Syn-Ake contains real snake venom.
Reality
Syn-Ake is a fully synthetic dipeptide derivative manufactured in a lab. It was designed to mimic the receptor-blocking activity of waglerin-1 from Temple Pit Viper venom, but contains no animal-derived material and no actual venom. The 'snake venom peptide' marketing describes biomimetic design inspiration, not source.
Myth
Higher concentrations of Syn-Ake produce proportionally better wrinkle reduction.
Reality
Stratum corneum permeation is the rate-limiting step, not vehicle concentration. Above the manufacturer's tested 4% range, additional peptide in the serum mainly increases label appeal. Vehicle and formulation choices (encapsulation, penetration enhancers, occlusion) drive delivered dose more than nominal label percentage.
Myth
Syn-Ake can be safely injected for a stronger effect.
Reality
Cosmetic Syn-Ake preparations are not sterile injectable products, not manufactured under injectable standards, and there is no authorized injectable category. Injecting cosmetic peptide products carries documented infection risk — published case reports exist for related cosmetic peptides (Argireline) causing serious facial mycobacterial infection after unlicensed injection.
Myth
Stacking Syn-Ake with Vialox and Argireline triples the wrinkle-reduction effect.
Reality
Syn-Ake and Vialox both target the postsynaptic nmAChR — stacking them likely produces redundant occupancy of the same target rather than additive benefit. Combining a postsynaptic receptor blocker with a presynaptic SNARE inhibitor (Argireline) is mechanistically more complementary, but clinical evidence that multi-peptide stacks meaningfully outperform a single well-formulated cosmetic peptide is limited.
Published Research
3 studiesThe effect of a serum containing acetyl hexapeptide-8, dipeptide diaminobutyroyl benzylamide diacetate and gluconolactone on skin biomarkers, wrinkles and skin texture.
Anti-aging activity of Syn-Ake peptide by in silico approaches and in vitro tests.
Viper Venom and Synthetic Peptides: Emerging Active Ingredients in Anti-Ageing Cosmeceuticals.
Quick Facts
- Class
- Cosmeceutical Peptide
- Tier
- D
- Evidence
- Preliminary
- Safety
- Moderate Data
- Updated
- Apr 2026
- Citations
- 3PubMed
Also known as
Tags
Peptide Families
Related Goals
Conditions Discussed
Evidence Score
Clinical Trials
View Clinical TrialsLinks to ClinicalTrials.gov for reference. Listing does not imply endorsement.